Immunogenic Cell Death in Canine Lung Cancer: A Comparative
Veterinary Oncology (Review of Animal Models and Human NSCLC)
Hangao Sun1, Qing He2, Ziye Zhu2
and Yuju Bai1*
1Department
of Oncology, The Second Affiliated Hospital of Zunyi Medical
University, Zunyi 563006, China; 2College of Veterinary
Medicine, Nanjing Agricultural University, Nanjing, 210095, China;
2College of Veterinary Medicine, Nanjing Agricultural
University, Nanjing, 210095, China
Primary canine lung carcinoma is uncommon but clinically aggressive and may
provide a spontaneous, immunocompetent model for human non-small cell lung
cancer (NSCLC). This review evaluated evidence that targeted therapies induce
immunogenic cell death (ICD) across human, canine, and murine lung cancer models
and examined conserved tumor-microenvironment barriers to ICD-driven immunity.
PubMed, Scopus, and Web of Science were searched for peer-reviewed studies
published from January 2000 to June 2026 that assessed canonical ICD hallmarks—calreticulin
exposure, ATP release, HMGB1 release, or type I interferon signaling—after
targeted therapy. Eligible studies were synthesized narratively and
comparatively. Seventy-five studies were synthesized. Results are organized into
five thematic areas: (1) canine lung carcinoma as a spontaneous veterinary
disease model, (2) veterinary and companion-animal evidence relevant to ICD, (3)
human NSCLC evidence as a comparative reference, (4) conserved immune and
stromal barriers across species and (5) animal-model evidence informing future
veterinary trials.The synthesis reveals that while the
molecular machinery for ICD induction and sensing is highly conserved, the tumor
microenvironment—dominated by macrophage-mediated efferocytosis—constitutes the
critical rate-limiting checkpoint for translating ICD into anti-tumor immunity
across all species examined. Available evidence supports cross-species
conservation of major ICD pathways and suggests that canine lung cancer may be
useful for investigating mechanisms that limit ICD-driven immunity.
Nevertheless, the reproducibility, clinical relevance, and therapeutic benefit
of combining ICD-inducing agents with microenvironment-targeted treatments in
dogs remain uncertain and require validation in larger, controlled prospective
studies.
To Cite This Article:
Sun H, He Q, Zhu Z and Bai Y,
2026. Immunogenic cell death in canine
lung cancer: a comparative veterinary oncology (Review of animal models and
human NSCLC). Pak Vet J, 46(8): 1883-1892. http://dx.doi.org/10.29261/pakvetj/2026.199